Abstract
Respiratory syncytial virus (RSV) is recognized as an important cause of lower and upper respiratory tract infections in older adults, and a successful vaccine would substantially lower morbidity and mortality in this age group. Recently, two vaccine candidates based on soluble purified glycoprotein F (RSV F), either alone or adjuvanted with glucopyranosyl lipid A formulated in a stable emulsion (GLA-SE), failed to reach their primary endpoints in clinical efficacy studies, despite demonstrating the desired immunogenicity profile and efficacy in young rodent models. Here, one of the RSV F vaccine candidates (post-fusion conformation, RSV post-F), and a stabilized pre-fusion form of RSV F (RSV pre-F, DS-Cav1) were evaluated in aged BALB/c mice. Humoral and cellular immunogenicity elicited after immunization of naïve, aged mice was generally lower compared to young animals. In aged mice, RSV post-F vaccination without adjuvant poorly protected the respiratory tract from virus replication, and addition of GLA-SE only improved protection in the lungs, but not in nasal turbinates. RSV pre-F induced higher neutralizing antibody titers compared to RSV post-F (as previously reported) but interestingly, RSV F-specific CD8 T cell responses were lower compared to RSV post-F responses regardless of age. The vaccines were also tested in RSV seropositive aged mice, in which both antigen forms similarly boosted neutralizing antibody titers, although GLA-SE addition boosted neutralizing activity only in RSV pre-F immunized animals. Cell-mediated immune responses in the aged mice were only slightly boosted and well below levels induced in seronegative young mice. Taken together, the findings suggest that the vaccine candidates were not able to induce a strong anti-RSV immune response in recipient mice with an aged immune system, in agreement with recent human clinical trial results. Therefore, the aged mouse model could be a useful tool to evaluate improved vaccine candidates, targeted to prevent RSV disease in older adults.
Highlights
Respiratory Syncytial Virus (RSV) is an important cause of acute lower respiratory tract infection in young children, immunocompromised individuals, and older adults [1,2,3]
Most preclinical studies related to the development of RSV vaccines for older adults have been performed in young, RSV seronegative rodent models and have demonstrated the potential for RSV F antigen in a pre- or post-conformation to induce a strong and protective immune response, especially in the presence of an adjuvant [18, 21, 23, 25]
We demonstrated in RSV seronegative aged mice that addition of GLA-SE to RSV post-F induced higher neutralization titers than antigen alone, fully protected the lungs from viral replication, but only modestly induced F specific CD4 and CD8 T
Summary
Respiratory Syncytial Virus (RSV) is an important cause of acute lower respiratory tract infection in young children, immunocompromised individuals, and older adults [1,2,3]. Cherukuri et al, showed that levels of RSV F protein-specific IFN-γproducing T cells were lower in older individuals (65 to 85 years old) than in young adults (20 to 35 years old) [13], suggesting that deficient RSV F-specific T cell responses might increase susceptibility to severe RSV disease in the older adult population. An alum adjuvanted RSV post-F subunit vaccine evaluated in aged BALB/c mice showed reduced immunogenicity compared to young mice, suggesting that subunit vaccines developed for the older adult population might require a strong adjuvant to overcome immunosenescence, to achieve protective neutralizing antibody titers, and a Th1-biased cytokine response to limit lung inflammation [15]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
